A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Trial Profile

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs BLU-667 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms ARROW
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 02 May 2018 According to a Blueprint Medicines media release, the enrollment in the dose expansion portion of the study is ongoing.
    • 02 May 2018 According to a Blueprint Medicines media release, initial data from this study were presented at the American Association for Cancer Research ( AACR ) Annual Meeting.
    • 15 Apr 2018 Results presented in a Blueprint Medicines Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top